Skip to main content
SpringerLink
Log in

Phase II trial of acivivin in patients with advanced epithelial ovarian carcinoma

A Gynecologic Oncology Group study

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Twenty-four evaluable patients with epithelial ovarian cancer resistant to primary therapy, or relapsing after response to initial therapy, were treated with acivicin utilizing a daily \xs 5 schedule. One patient achieved a partial response lasting five months; the remaining 23 patients showed no objective response. Profound and dose-limiting neurological toxicity was seen in 11 patients. Acivicin is inactive in patients with previously treated ovarian cancer and has a poor therapeutic index due to neurologic adverse effects in this patient population. The profound neurotoxicity may be related to prior therapy with cisplatin, to protein binding in ascitic fluid accumulations or to yet undefined parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Houchens DP, Ovejera AA, Sheridan MA, Johnson RK, Bogden AE, Neil GL: Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125. Cancer Treat Rep 63:473–476, 1979

    Google Scholar 

  2. Jayaram HN, Cooney DA, Ryan JA, Neil G, Dion RL, Bono VH: L-(S, 5S)-amino-3-chloro-4,5-dihydro-5-isoxazolacetic acid (NSC-163501): A new amino acid antibiotic with the properties of an antagonist of L-glutamine. Cancer Chemother Rep 59:481–491, 1975

    Google Scholar 

  3. Poster DS, Bruno S, Penta J, Neil GL, McGovren JP: Acivicin: An antitumor antibiotic. Cancer Clin Trials 4:327–330, 1981

    Google Scholar 

  4. McGovren JP, Neil GL, Sem PC, Stewart JC: Sex and age related mouse toxicity and disposition of the amino acid antitumor agent, acivicin. J Pharmacol Exp Ther 216:433–440, 1981

    Google Scholar 

  5. O'Dwyer PJ, Alonso MT, Leyland-Jones B: Acivicin: A new glutamine antagonist in clinical trials. J Clin Oncol 2, 9:1064–1071, 1984

    Google Scholar 

  6. Sridhar KS, Ohnuma T, Chahinian AP, Holland JF: Phase I study of acivicin in patients with advanced cancer. Cancer Treat Rep 67:701–703, 1983

    Google Scholar 

  7. Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J: Cis-dichlorodiammineplatinum (II) in the treatment of gynecologic malignancies: Phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 63:1549–1555, 1979

    Google Scholar 

  8. Fleishman G, Yap HY, Murphy SK, Bodey G: Phase II trial of acivicin in advanced metastatic breast cancer. Cancer Treat Rep 67:843–844, 1983

    Google Scholar 

  9. Adolphson C, Bedikian AY, Stroehlein JR, Karlin DA, Bodey GP, Hickey RC: Phase II evaluation of acivicin (AT-125, NSC 163501) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1:96, 1982

    Google Scholar 

  10. Earhart RH, Koeller JM, David TE, Borden EC, McGovren JP, Davis HL and Tormey DC: Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion. Cancer Treat Rep 67:683–692, 1983

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Medical Oncology, John Hopkins Oncology Center, Baltimore, MD, USA

    William P. McGuire (Associate Professor of Oncology)

  2. Gynecologic Oncology Group, Cancer Research Scientist V, Roswell Park Memorial Institute, Buffalo, NY, USA

    John A. Blessing (Group Statistician)

  3. Department of Obstetrics and Gynecology, University of California at Irvine, Irvine, CA, USA

    Philip J. DiSaia (Professor and Chairman)

  4. Division of Gynecologic Oncology, University of Pittsburgh, Magee Womens Hospital, Pittsburg, PA, USA

    Herbert J. Buchsbaum (Professor of Obstetrics and Gynecology, Director)

Authors
  1. William P. McGuire
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John A. Blessing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip J. DiSaia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Herbert J. Buchsbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

McGuire, W.P., Blessing, J.A., DiSaia, P.J. et al. Phase II trial of acivivin in patients with advanced epithelial ovarian carcinoma. Invest New Drugs 4, 49–52 (1986). https://doi.org/10.1007/BF00172016

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00172016

Key words

Search

Navigation